JP2018504141A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504141A5
JP2018504141A5 JP2017556782A JP2017556782A JP2018504141A5 JP 2018504141 A5 JP2018504141 A5 JP 2018504141A5 JP 2017556782 A JP2017556782 A JP 2017556782A JP 2017556782 A JP2017556782 A JP 2017556782A JP 2018504141 A5 JP2018504141 A5 JP 2018504141A5
Authority
JP
Japan
Prior art keywords
government
awarded
health
certain rights
national institutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013765 external-priority patent/WO2016118433A1/en
Publication of JP2018504141A publication Critical patent/JP2018504141A/ja
Publication of JP2018504141A5 publication Critical patent/JP2018504141A5/ja
Pending legal-status Critical Current

Links

JP2017556782A 2015-01-20 2016-01-17 非標的化アデノウイルス変異体および関連する方法 Pending JP2018504141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105284P 2015-01-20 2015-01-20
US62/105,284 2015-01-20
PCT/US2016/013765 WO2016118433A1 (en) 2015-01-20 2016-01-17 Detargeted adenovirus variants and related methods

Publications (2)

Publication Number Publication Date
JP2018504141A JP2018504141A (ja) 2018-02-15
JP2018504141A5 true JP2018504141A5 (enExample) 2019-02-07

Family

ID=56417617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556782A Pending JP2018504141A (ja) 2015-01-20 2016-01-17 非標的化アデノウイルス変異体および関連する方法

Country Status (4)

Country Link
US (3) US10376549B2 (enExample)
EP (1) EP3247807B1 (enExample)
JP (1) JP2018504141A (enExample)
WO (1) WO2016118433A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
RS64059B1 (sr) 2016-03-31 2023-04-28 The European Molecular Biology Laboratory Protein adenoviralnog omotača izveden iz vehikuluma za isporuku
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3812465A1 (en) 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
AU1449792A (en) * 1991-02-14 1992-09-15 La Jolla Cancer Research Foundation A novel integrin specificity for the hiv tat protein
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
WO2001091802A1 (en) * 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
US7556925B2 (en) * 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
EP1446479B1 (en) * 2001-09-29 2012-08-15 Chae-Ok Yun Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
EP1516055A4 (en) * 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
JP4328116B2 (ja) * 2003-03-25 2009-09-09 国立医薬品食品衛生研究所長 変異型アデノウイルスベクター
US20060281090A1 (en) * 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
US20110104788A1 (en) * 2008-02-07 2011-05-05 Andrew Baker Modulation of Adenoviral Tropism
WO2011057248A2 (en) * 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use

Similar Documents

Publication Publication Date Title
JP2021503478A5 (enExample)
JP2021502979A5 (enExample)
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
JP2021500894A5 (enExample)
JP2018012698A5 (enExample)
JP2020010717A5 (enExample)
JP2018100276A5 (enExample)
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
JP2016196495A5 (enExample)
JP2018533683A5 (enExample)
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
JP2016028081A5 (enExample)
JP2019536002A5 (enExample)
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
LT3204413T (lt) Nešiklio ir antikūno kompozicija, ir jos gamybos bei naudojimo būdai
WO2015153513A8 (en) Anti-ox40 antibodies and methods of use
JP2017537928A5 (enExample)
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
MX2019006334A (es) Anticuerpos antitau y métodos de uso.
TWD173737S (zh) 肌肉鍛鍊機器
JP2018064407A5 (enExample)
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej